What the Facts with Argenica Therapeutics: How can we advance after-stroke care?

What are strokes? How many people do they impact? And what are the limitations of current treatments? 

Host Tylah Tully is joined in this episode by Argenica Therapeutics (ASX:AGN) managing director Dr Liz Dallimore, who shares all about the devastating global impact of strokes and the company’s innovative approach to treatment.

Dallimore explains what happens in the brain during a stroke, why cases are rising worldwide, and the limitations of current treatments.

She also explains how Argenica’s neuroprotective drug works, which aims to protect brain cells and extend the treatment window for stroke patients; potentially transforming outcomes.

With a Phase II trial nearing results, Argenica is positioning itself at the forefront of stroke therapy innovation.

This video was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.